At IgGenix, our mission is to develop a first-in-class therapy for millions of people whose daily lives are limited by food allergies and other severe allergic conditions.

Starting from a deep understanding of molecular immunology, we employ an antibody-based therapeutic platform to potentially enable faster, deeper and more sustained clinical responses. We push the limits of single-cell genomic technology to capture and analyze very rare human B cells expressing allergen binding antibodies. We engineer these antibodies to uniquely capture allergens and endow them with powerful immune modulating activities derived from the IgG antibody class to suppress allergic reactions. Our team is at work today to make this new life changing therapy tomorrow’s reality.

The IgGenix Team


Jessica Grossman, M.D

Chief Executive Officer

Henry Lowman, Ph.D.

Chief Scientific Officer

Derek Croote, Ph.D.

Chief Technical Officer


Stephen Quake, D. Phil.

Stanford University; Chan Zuckerberg Biohub


Samir Kaul

Khosla Ventures

Stephen Quake, D. Phil.

Stanford University; Chan Zuckerberg Biohub


Kari Nadeau, M.D., Ph.D., F.A.A.A.A.I. (Chairperson)

Stanford University

Hans Oettgen, M.D., Ph.D.

Harvard Medical School

Stephen Quake, D. Phil.

Stanford University; Chan Zuckerberg Biohub

Scott Smith, M.D., Ph.D.

Vanderbilt University

Dale Umetsu, M.D., Ph.D.

Stanford University; University of California, San Francisco

Jim Wells, Ph.D.

University of California, San Francisco


IgGenix is taking a revolutionary approach to directly address food allergies by re-engineering key antibodies involved in the allergic cascade. We believe we can truly change the face of allergic disease, empowering people to live life without the constant fear of a life-threatening allergic reaction.

Recent studies indicate that food allergies affect more than 200 million individuals worldwide, including 11% of adults and between 4-11% of infants and young children in the United States. Every two to three minutes, there is an emergency room visit related to food induced anaphylaxis, and food allergies result in a cost to the U.S. economy of $24.8 billion annually. In addition, related hospitalization rates have increased 265% in a ten-year period.

Few options exist for adults and children who suffer from severe food allergies, and none exist that treat the underlying mechanism of disease. In individuals with allergies, specialized B cells produce IgE antibodies to each specific allergen. The IgE antibodies bind to mast cells, initiating what can be a life-threatening cascade when an individual is exposed to an allergen. This cascade happens quickly and can result in anaphylaxis and even death.

Through its unique technology, IgGenix isolates and re-engineers allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent an allergic cascade. Through this completely novel approach to treating allergic disease, IgGenix’s treatments may be able to effectively block and even prevent life-threatening allergic reactions, while at the same time elucidating the role of the allergens themselves.



Khosla Ventures
Parker Ventures


We are a small, innovative and passionate team working in a fast-paced environment at the forefront of allergy immunology. We have exciting opportunities for enthusiastic, self-motivated, and detail-oriented individuals to join the growing team at IgGenix. IgGenix offers competitive compensation, comprehensive benefits, equity, and the opportunity for growth.

Scroll through our list of open positions and apply today!

For more information contact us at


IgGenix, Inc
329 Oyster Point Blvd., 3rd Floor
South San Francisco, CA 94080